Mar Rhino

Xylometazoline Hydrochloride, the active ingredient in Mar Rhino, is an alpha‑adrenergic agonist presented as a nasal decongestant for nasal use. It relieves congestion caused by the common cold, sinusitis, and allergic rhinitis in adults and children.

GNH USA supplies Mar Rhino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mar Rhino, an alpha‑adrenergic nasal decongestant, is employed to reduce swelling of the nasal mucosa in several common upper‑respiratory conditions.

- Common cold nasal congestion: reduces swelling of nasal passages to improve airflow. - Sinusitis‑related congestion: alleviates blockage and pressure within the nasal cavity. - Allergic rhinitis: diminishes nasal swelling and congestion associated with allergic responses.

Adverse reactions may occur with any nasal decongestant. Most are mild and reversible, but rare events can be serious.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing shortly after application. - Mild headache.

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) after prolonged use. - Elevated blood pressure or tachycardia. - Severe allergic reaction such as anaphylaxis. - Persistent nasal ulceration.

Before using Mar Rhino, consider the following safety measures.

- Use duration: limit use to 3‑5 days to avoid rebound congestion. - Age restrictions: not recommended for children under 2 years unless directed by a clinician. - Pregnancy: safety not established; consult a healthcare professional before use. - Cardiovascular disease: use with caution due to possible systemic vasoconstriction. - Drug interactions: avoid concurrent use with other nasal decongestants or MAO inhibitors. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mar Rhino may interact with other medicines that affect the sympathetic nervous system.

Major Interactions (Avoid): - Concurrent use with monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Use with other topical nasal decongestants (e.g., oxymetazoline): increased chance of rebound congestion.

Moderate Interactions (Monitor Closely): - Systemic sympathomimetics (e.g., pseudoephedrine): may enhance cardiovascular effects. - Beta‑blockers: may blunt tachycardia but require blood‑pressure monitoring. - Tricyclic antidepressants: potential additive vasoconstrictive effect.